Pharmacosmos’ Monoferric 1000 mg IV Receives Health Canada Marketing Approval

 Pharmacosmos’ Monoferric 1000 mg IV Receives Health Canada Marketing Approval

Pharmacosmos’ Monoferric 1000 mg IV Receives Health Canada Marketing Approval

Shots:

  •  Monoferric is being approved for anaemic adult patients intolerant or unresponsive to iron oral therapy with an expection to reach market by Nov 2018
  • In 2015, Pharmacosmos signed Canada commercialization rights of Monoferric to Pfizer Canada
  • Monoferric IV has a novel matrix structure of linear isomaltoside chains interspersed with Fe3+ and already being marketed in >30 countries worldwide

Click here to read full press release/ article | Ref: Pharmacosmos | Image:  Pharmacosmos

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post